下一代肽受体放射性核素治疗:177Lu-DOTA-EB-TATE的1期剂量递增与剂量学研究
这项1期研究纳入6例晚期胃肠胰神经内分泌肿瘤患者,采用3+3剂量递增设计给予177Lu-DOTA-EB-TATE 1.85、3.70或5.55 GBq,每6周1次共2周期。治疗耐受良好、无肾毒性,但血液学毒性为剂量限制性,最大耐受活度为3.70 GBq、推荐2期活度为每周期1.85 GBq;3个月时5例疾病稳定、1例部分缓解,6个月时2例进展。
要点
- 最大耐受活度为3.70 GBq,推荐2期活度为每周期1.85 GBq。
- 每周期肾脏中位吸收剂量4.8 Gy(范围2.9-8.9 Gy),未见肾毒性。
- 血液学毒性为剂量限制性,骨髓成为剂量限制器官。
核心结论
- 2周期177Lu-DOTA-EB-TATE方案较标准177Lu-DOTATATE给予更高的肾脏吸收剂量,个体化剂量学下未见肾毒性。
- 循环滞留增加导致血液学副作用,使骨髓成为剂量限制器官。
- 在本研究限定剂量范围内,该药是标准PRRT潜在的高摄取替代方案,支持缩短为2周期以便更早评估疗效。
研究设计与样本
- 1期剂量递增与剂量学研究,纳入6例不可手术、可测量的胃肠胰NET(WHO 2级和3级)且生长抑素受体过表达成人患者。
- 采用3+3剂量递增设计,静脉给予177Lu-DOTA-EB-TATE名义活度1.85、3.70或5.55 GBq,共2周期、间隔6周。
- 第一周期后个体化剂量学指导后续治疗给药;每两周评估安全性,3和6个月用RECIST评估肿瘤反应。
主要发现
- 治疗耐受良好,副作用轻微,包括恶心、乏力、脱发;未发生肾毒性。
- 每周期肾脏中位吸收剂量4.8 Gy(范围2.9-8.9 Gy;均值2.2 Gy/GBq)。
- 血液学毒性为剂量限制性,3.7 GBq时1例出现持续性3级发热性中性粒细胞减少,并在外部队列中得到确认。
- 3个月时肿瘤反应为疾病稳定5例、部分缓解1例;治疗完成后6个月时2例疾病进展。
关键数值与推荐
- 最大耐受活度设为3.70 GBq,推荐2期活度为每周期1.85 GBq以避免不可逆骨髓抑制。
- 每周期肾脏中位吸收剂量4.8 Gy(范围2.9-8.9 Gy;均值2.2 Gy/GBq)。
- 3个月疗效评估:疾病稳定5例、部分缓解1例;6个月时2例进展。
临床怎么用
- 在限定剂量范围内可考虑将177Lu-DOTA-EB-TATE作为高摄取替代方案,采用2周期缩短方案。
- 应结合个体化剂量学给药,并重点监测血液学毒性以平衡疗效与安全。
局限性
- 样本量仅6例,剂量递增结论需更大研究验证。
- 需进一步研究优化给药方案与患者选择以平衡疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neuroendocrine tumors (NETs) are often detected late, limiting curative treatments and requiring systemic therapies such as peptide receptor radionuclide therapy (PRRT). Although 177Lu-DOTATATE has demonstrated efficacy, its rapid clearance from the circulation limits tumor radiation delivery and may increase renal toxicity risk. 177Lu-DOTA-EB-TATE, a novel PRRT agent conjugated with Evans blue for albumin binding, offers extended circulation time and enhanced tumor uptake, potentially improving therapeutic outcomes. This phase 1 study aimed to evaluate the safety, dosimetry, and preliminary efficacy of 177Lu-DOTA-EB-TATE in patients with advanced gastroenteropancreatic NETs. Methods: Six adults with inoperable, measurable gastroenteropancreatic NETs (WHO grades 2 and 3) and with somatostatin receptor overexpression were enrolled. Using a 3 + 3 dose-escalation design, patients received 177Lu-DOTA-EB-TATE at nominal activities of 1.85, 3.70, or 5.55 GBq intravenously for 2 cycles, 6 wk apart. Individualized dosimetry after the first cycle informed subsequent treatment delivery. Safety was assessed biweekly, and tumor responses were evaluated using RECIST at 3 and 6 mo. Results: Treatment was well-tolerated, with mild side effects, including nausea, fatigue, and hair loss; no renal toxicity occurred. The median kidney absorbed dose per cycle was 4.8 Gy (range, 2.9-8.9 Gy; mean, 2.2 Gy/GBq). Hematologic toxicity was dose-limiting, with persistent grade 3 febrile neutropenia observed at 3.7 GBq in 1 patient and confirmed in an external cohort. Thus, the maximum tolerated activity was set at 3.70 GBq and the recommended phase 2 activity at 1.85 GBq per cycle to avoid irreversible marrow suppression. Tumor responses included stable disease (n = 5) and partial response (n = 1) at 3 mo; disease progressed in 2 patients at 6 mo after treatment completion. Conclusion: The 2-cycle regimen of 177Lu-DOTA-EB-TATE delivered higher renal absorbed doses compared with standard 177Lu-DOTATATE. With individualized dosimetry, no kidney toxicity was observed. However, increased retention in the circulation caused hematologic-related side effects and made marrow the dose-limiting organ. Within the defined dosing limits of this study, 177Lu-DOTA-EB-TATE is a potential high-uptake alternative to standard PRRT, supporting a shortened 2-cycle schedule for earlier response assessment. Further research should refine dosing schedules and patient selection to balance efficacy and safety.
引用
- Bodei L, Zanzonico P, Krebs S, et al. Next-Generation Peptide Receptor Radionuclide Therapy: A Phase 1 Dose-Escalation and Dosimetry Study of 177Lu-DOTA-EB-TATE. J Nucl Med. 2026. PMID: 42785949. doi:10.2967/jnumed.126.272756
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。